ANDA 70852, held by Actavis Elizabeth. Hydrochlorothiazide; Propranolol Hydrochloride.
As of Nov 22, 2026, ANDA 70852 (Propranolol Hydrochloride and Hydrochlorothiazide), held by Actavis Elizabeth, was first approved by FDA on May 15, 1986, with 14 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 15, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Propranolol Hydrochloride and Hydrochlorothiazide25MG;80MG · tablet;oral | Hydrochlorothiazide; Propranolol Hydrochloride | Discontinued |
| Aug 26, 2002 | Supplement 17Labeling | Approved | None posted |
| Nov 2, 2001 | Supplement 14Manufacturing | Approved | None posted |
| Jun 13, 2001 | Supplement 13Labeling | Approved | None posted |
| Aug 11, 1998 | Supplement 12Labeling | Approved | None posted |
| Jan 18, 1996 | Supplement 11Manufacturing | Approved | None posted |
| Nov 21, 1991 | Supplement 10Labeling | Approved | None posted |
| Sep 18, 1991 | Supplement 9Labeling | Approved | None posted |
| Aug 15, 1989 | Supplement 6Manufacturing | Approved | None posted |
| Aug 15, 1989 | Supplement 7Manufacturing | Approved | None posted |
| Aug 15, 1989 | Supplement 8Manufacturing | Approved | None posted |
| Nov 8, 1988 | Supplement 2Manufacturing | Approved | None posted |
| Nov 8, 1988 | Supplement 3Manufacturing | Approved | None posted |
| Nov 8, 1988 | Supplement 5Labeling | Approved | None posted |
| Apr 17, 1987 | Supplement 1Manufacturing | Approved | None posted |
| May 15, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters